Sarah E Aylett, Helen Cross, Dave Berry
Index: Dev. Med. Child Neurol. 48(7) , 612-5, (2006)
Full Text: HTML
A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0.75mg/kg/day. Concurrent antiepileptic medication was lamotrigine at 13mg/kg/day. Clobazam plasma levels were within the normal range, while N-desmethylclobazam (DCLB) concentrations were between five and seven times above the upper limit of the normal range. The plasma elimination half-life for DCLB was prolonged, suggesting a genetic variability in DCLB metabolism leading to toxicity. Reduction in the dose of clobazam to 0.3mg/kg/day was associated with resolution of the non-epileptic neurological symptoms, reduction in DCLB plasma levels, and maintenance of seizure control.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
N-Desmethyl Clobazam
CAS:22316-55-8 |
C15H11ClN2O2 |
Blood concentrations of clobazam and norclobazam in a lethal...
2010-11-01 [Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)] |
Simultaneous determination of clobazam and its major metabol...
2005-09-05 [J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)] |
A major influence of CYP2C19 genotype on the steady-state co...
2004-12-01 [Brain Dev. 26(8) , 530-4, (2004)] |
Analysis of clobazam and its active metabolite norclobazam i...
1996-11-01 [Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)] |
HPLC method for simultaneous determination of clobazam and N...
1989-03-01 [Biomed. Chromatogr. 3(2) , 79-81, (1989)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved